Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) has announced that the U.S. Food and Drug Administration (FDA) has approved pegcetacoplan injection (labelled “SYFOVRE”), for the treatment of… Read More »Apellis Pharmaceuticals announce the approval of pegcetacoplan injection for the treatment of geographic atrophy (GA).
Researchers have announced recruitment of the first patient in a clinical trial of a an experimental AAV gene therapy for the treatment of X-linked retinitis… Read More »A phase I/II study has announced the recruitment of the first patient for a novel AAV-RPGR treatment for X-linked retinitis pigmentosa.
Researchers at the Department of Ophthalmology, Medical University Graz, Austria and the Department of Ophthalmology, University of Basel, Switzerland, have reported that fundus auto-fluorescence (FAF)… Read More »Fundus autofluorescence assessment tracks Stargardt disease progression for a 24-month period.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the February 19th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »February 19th, 2023 “EURETINA-Brief”© Issue No. 266
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced the publication of updated efficacy results from a pooled analysis of… Read More »GenSight Biologics announces a pooled presentation of LUMEVOQ versus natural history in ND4-LHON.
Researchers at the Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, have reported that outcome measures for future clinical trials should include evaluations… Read More »Outcome measures for future trials for autosomal dominant vitelliform macular dystrophy caused by BEST1 mutations.
Researchers at the Seoul National University College of Medicine, Republic of Korea, have demonstrated a proof-of-principle using “base editing” (BEs) to address Leber congenital amaurosis… Read More »Visual function restoration for a pre-clinical in vivo IRD model using a novel therapeutic “base editing”.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 30th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »January 30th, 2023 “EURETINA-Brief”© Issue No. 265
A French bioelectronics company “Pixium Vision SA” (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), based in Paris, has announced the completion of implantations of an… Read More »Pixium SA has announced the completion of implantations of the “PRIMAvera” trial with the implantation of a bionic artificial retina.
Researchers at the UCL Institute of Ophthalmology, London and Moorfields Eye Hospital NHS Foundation Trust has reported a novel history of RP2 mutations arising from… Read More »A natural history of XLRP from RP2 mutations aim to facilitate trial endpoints for future clinical studies.